Form 4: Halozyme COO Receives Equity Compensation

Cortney Caudill, SVP and Chief Operating Officer of Halozyme Therapeutics, was granted 9,031 stock options and 3,625 restricted stock units on October 3, 2025.

Summary

• Cortney Caudill, SVP, Chief Operating Officer of Halozyme Therapeutics, Inc. (HALO), reported an acquisition of derivative securities.
• On October 3, 2025, Caudill was granted an option to purchase 9,031 shares of common stock with an exercise price of $68.98 per share.
• This option vests one-fourth on October 3, 2026, and then 1/48th monthly thereafter, with an expiration date of October 3, 2035.
• Additionally, Caudill was granted 3,625 Restricted Stock Units (RSUs) on October 3, 2025.
• These RSUs vest one-fourth on the first anniversary of the grant date (October 3, 2026) and then one-fourth on each anniversary date thereafter.

Sentiment

Score: 6

Explanation: The filing reports a routine executive equity grant, which is generally viewed as a positive for aligning management and shareholder interests, but it does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The equity grants align the interests of a key executive, Cortney Caudill, with those of shareholders, incentivizing long-term company performance.
• The vesting schedules for both options and RSUs promote executive retention over several years.

Negatives

• No explicit negatives are presented in this Form 4 filing, which is purely a disclosure of insider transactions.

Risks

• The value of the granted options and RSUs is subject to the future performance of Halozyme's common stock, meaning the actual realized value could be lower than the grant date value if the stock price declines.
• Potential for minor dilution risk for existing shareholders from the issuance of new shares upon option exercise or RSU vesting, though this specific grant is relatively small.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a disclosure of an insider's equity transaction.

Industry Context

Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. These incentives are designed to attract, retain, and motivate key talent by linking their personal financial success to the long-term performance of the company's stock, a common practice in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The use of stock options and Restricted Stock Units (RSUs) for executive compensation is a widely adopted practice in the biotechnology sector, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen, which frequently utilize similar equity-based incentives to align executive and shareholder interests.
• The vesting schedules, typically over several years, are consistent with industry norms aimed at promoting long-term executive retention and performance, similar to those observed in peer companies' proxy statements.
• The specific number of shares granted and the option exercise price would typically be benchmarked against peer group compensation data, though this filing does not provide the context for such a comparison.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting/exercise, but also benefit from increased executive alignment and motivation for long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• Continued vesting of the granted stock options and Restricted Stock Units according to their respective schedules.
• Potential exercise of stock options by the reporting person once they become exercisable.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Form 4, Insider Transaction, Equity Grant, Stock Option, Restricted Stock Units, Executive Compensation, Cortney Caudill, Biotechnology